Plain-English translation of NCT06186414 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to treat bladder cancer that hasn't responded to standard BCG treatment. The study will test whether works better when given alone or combined with BCG, and will also check what side effects it causes. Researchers will start by testing different doses to find the safest level, then expand the study to see how well the medication actually works.
Many patients with non-muscle-invasive bladder cancer don't respond well to the standard BCG treatment, and these patients have limited options. This trial exists to see if this new medication can help patients whose cancer has stopped responding to current therapies.
You likely qualify if…
You likely don't qualify if…
Participants will receive the new medication directly into the bladder through a catheter during clinic visits. Depending on which group you're in, you may receive the medication alone or combined with standard BCG treatment. The study has two phases: first, doctors will test different doses to find the safest level, then expand to larger groups to see how well the treatment works. You'll have regular follow-up visits to monitor your cancer and check for side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China